Recent

% | $
Quotes you view appear here for quick access.

Inovio Pharmaceuticals, Inc. Message Board

  • dankrell dankrell Mar 15, 2013 6:36 PM Flag

    This info. was on my TD Ameritrade account. This is great news for INO!

    Mentor Capital Cancer Immunotherapy Index Gains 32% YTD and Adds Second Generation Firms for 2013
    12:51p ET March 15, 2013 (Business Wire) Mentor Capital, Inc. (Pink Sheets:MNTR) reports that for 2013 it has added Galena Biopharma Corporation (NASDAQ:GALE), NewLink Genetics Corporation (NASDAQ:NLNK), Vical Incorporated (NASDAQ:VICL) and Inovio Pharmaceuticals, Inc. (NYSE MKT:INO) to its proprietary Cancer Immunotherapy Index. The four firms and others in the Index represent the second generation immunotherapy knowledge that has evolved since 2009 when Mentor Capital first published.

    Year-to-date, the now fifteen Cancer Index members have posted an average 32% gain (161% Annualized). This is more than double the 15% average YTD appreciation of the NASDAQ, S&P, and NYSE Biotech Indices.

    The Mentor Capital Cancer Immunotherapy Index companies and their performance for the first ten weeks of 2013 follow: Galena Biopharma Corporation +39.87%, NewLink Genetics Corporation +0.08%, Vical Incorporated +43.30%, Inovio Pharmaceuticals, Inc. +7.65%, Dendreon (NASDAQ:DNDN) +10.40%, Immunocellular Therapeutics, Ltd. (NYSE MKT:IMUC) +40.10%, Agenus (NASDAQ:AGEN) +6.59%, Oncothyreon (NASDAQ:ONTY) +15.63%, Biovest International (Pink Sheets:BVTIQ) -56.00%, Celldex Therapeutics (NASDAQ:CLDX) +78.24%, Northwest Biotherapeutics (NASDAQ:NWBO) +17.96%, CEL - SCI Corp. (NYSE MKT:CVM) -4.44% , Generex Biotechnology (OTCBB:GNBT) +24.00% as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express, Provectus Pharmaceuticals, Inc. (Pink Sheets:PVCT) +40.18% and Advaxis, Inc. (OTCBB:ADXS) +199.67% - all for an average 2013 YTD gain of +31.85%. (Annualized rate: 161.48%).

    Mentor Capital, Inc., by acquisition or stock purchase, seeks to invest in leading-edge private and public cancer companies, and certain other situations. Mentor created the Cancer Immunotherapy Index July 10, 2009. Since then, it has invested or maintained a tracking position in all companies in the Can

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • This news does not occur based on what bashers have been trying to peddle. INO is a real viable entity.

      Sentiment: Strong Buy

      • 1 Reply to rehdvm2004
      • people don't get it. Listen this is biotech stock , biotech stocks are always risky but you know what think of it this way in a hypothetical way. Lets say Hep C doesn't turn out the we want it too the most it will drop too is maybe .30 cents a share. but you still have other stuff in the pipeline.

        But look at this way if the hep C phase 2 comes out superb your upside is unlimited. If the technology of electroporation and DNA is proven to work then this company will be valued in the billions because of everything in the pipeline Luekimia, HIV, Hep C . From there this will go up like INFI pharmaceuticals. No drugs in phase 3 or FDA approved drugs yet INFI trades at $41 a share. mark my words shorts you are missing out on a chance of a lifetime like PCYC.

        Sentiment: Strong Buy

 
INO
11.18+0.25(+2.29%)Apr 28 4:00 PMEDT